{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:38:23Z","timestamp":1780105103276,"version":"3.54.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s13555-025-01426-x","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:43:13Z","timestamp":1747284193000},"page":"1833-1849","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 Trials"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-1142","authenticated-orcid":false,"given":"John R.","family":"Ingram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Matusiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Kokolakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena B.","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine-Elke","family":"Ortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Llobet","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoba","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette","family":"Alarcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle C.","family":"Pieterse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Shayesteh","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Ioannides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B.","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"issue":"1","key":"1426_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R, Jemec GBE, Matusiak \u0141, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18.","journal-title":"Nat Rev Dis Primers"},{"key":"1426_CR2","doi-asserted-by":"crossref","unstructured":"Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J. 2014;90(1062):216\u201321; quiz 220.","DOI":"10.1136\/postgradmedj-2013-131994"},{"issue":"9","key":"1426_CR3","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/jdv.18163","volume":"36","author":"JR Ingram","year":"2022","unstructured":"Ingram JR, Bettoli V, Espy JI, et al. Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US. J Eur Acad Dermatol Venereol. 2022;36(9):1597\u2013605.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1426_CR4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1001\/jamadermatol.2021.1677","volume":"157","author":"A Jfri","year":"2021","unstructured":"Jfri A, Nassim D, O\u2019Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis. JAMA Dermatol. 2021;157(8):924\u201331.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1426_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/ced.14826","volume":"47","author":"N Kashetsky","year":"2022","unstructured":"Kashetsky N, Mukovozov IM, Pereira J, Manion R, Carter S, Alhusayen R. Patient experiences with hidradenitis suppurativa: the hidradenitis patient experience survey. Clin Exp Dermatol. 2022;47(1):72\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1426_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/bjd.21673","volume":"187","author":"HC Ring","year":"2022","unstructured":"Ring HC, Yao Y, Maul JT, et al. The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study. Br J Dermatol. 2022;187(4):523\u201330.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1426_CR7","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/ced\/llad191","volume":"48","author":"N Kearney","year":"2023","unstructured":"Kearney N, O\u2019Donohoe S, Hughes R, Kirby B.\u00a0Shorter time to initiation of biologic therapy in the setting of a hidradenitis suppurativa specialty clinic. Clin Exp Dermatol. 2023;48(10):1149\u201351.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"1426_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000508787","volume":"236","author":"G Kokolakis","year":"2020","unstructured":"Kokolakis G,\u00a0Wolk K, Schneider-Burrus S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. 2020;236(5):421\u201330.","journal-title":"Dermatology"},{"issue":"6","key":"1426_CR9","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/bjd.14038","volume":"173","author":"DM Saunte","year":"2015","unstructured":"Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546\u20139.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1426_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11916-017-0647-3","volume":"21","author":"ZS Patel","year":"2017","unstructured":"Patel ZS, Hoffman LK, Buse DC, et al. Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa [corrected]. Curr Pain Headache Rep. 2017;21(12):49.","journal-title":"Curr Pain Headache Rep"},{"issue":"2","key":"1426_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2340\/00015555-2815","volume":"98","author":"\u0141 Matusiak","year":"2018","unstructured":"Matusiak \u0141, Szcz\u0119ch J, Kaaz K, Lelonek E, Szepietowski JC. Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa. Acta Derm Venereol. 2018;98(2):191\u20134.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1426_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/bjd\/ljad104","volume":"189","author":"JS Kirby","year":"2023","unstructured":"Kirby JS,\u00a0Martorell A, Sayed CJ, et al. Understanding the real-world patient journey and unmet needs of people with hidradenitis suppurativa through social media research. Br J Dermatol. 2023;189(2):228\u201330.","journal-title":"Br J Dermatol"},{"key":"1426_CR13","doi-asserted-by":"crossref","unstructured":"Krajewski PK, Matusiak \u0141, von Stebut E, et al. Pain in hidradenitis suppurativa: a cross-sectional study of 1,795 patients. Acta Derm Venereol. 2021;101(1):adv00364.","DOI":"10.2340\/00015555-3724"},{"issue":"1","key":"1426_CR14","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/bjd.18656","volume":"182","author":"RM Nielsen","year":"2020","unstructured":"Nielsen RM,\u00a0Linds\u00f8 Andersen P, Sigsgaard V, Theut Riis P, Jemec GB. Pain perception in patients with hidradenitis suppurativa. Br J Dermatol. 2020;182(1):166\u201374.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1426_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jaad.2020.09.039","volume":"85","author":"KT Savage","year":"2021","unstructured":"Savage KT, Singh V, Patel ZS, et al. Pain management in hidradenitis suppurativa and a proposed treatment algorithm. J Am Acad Dermatol. 2021;85(1):187\u201399.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1426_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/AJP.0b013e3181ceb80c","volume":"26","author":"HS Smith","year":"2010","unstructured":"Smith HS, Chao JD, Teitelbaum J. Painful hidradenitis suppurativa. Clin J Pain. 2010;26(5):435\u201344.","journal-title":"Clin J Pain"},{"issue":"8","key":"1426_CR17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2340\/00015555-2967","volume":"98","author":"K Kaaz","year":"2018","unstructured":"Kaaz K, Szepietowski JC, Matusiak \u0141. Influence of itch and pain on sleep quality in patients with hidradenitis suppurativa. Acta Derm Venereol. 2018;98(8):757\u201361.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1426_CR18","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/bjd.18135","volume":"182","author":"E Keary","year":"2020","unstructured":"Keary E, Hevey D, Tobin AM. A qualitative analysis of psychological distress in hidradenitis suppurativa. Br J Dermatol. 2020;182(2):342\u20137.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1426_CR19","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1111\/bjd.16603","volume":"183","author":"\u0141 Matusiak","year":"2020","unstructured":"Matusiak \u0141. Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol. 2020;183(6):e171\u20137.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1426_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/bjd\/ljac018","volume":"188","author":"LAV Orenstein","year":"2023","unstructured":"Orenstein LAV, Salame N, Siira MR, et al. Pain experiences among those living with hidradenitis suppurativa: a qualitative study. Br J Dermatol. 2023;188(1):41\u201351.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1426_CR21","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1097\/DSS.0000000000001693","volume":"45","author":"CJ Puza","year":"2019","unstructured":"Puza CJ, Wolfe SA, Jaleel T. Pain management in patients with hidradenitis suppurativa requiring surgery. Dermatol Surg. 2019;45(10):1327\u201330.","journal-title":"Dermatol Surg"},{"issue":"10378","key":"1426_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week\u00a016 and week\u00a052 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase\u00a03 trials. Lancet. 2023;401(10378):747\u201361.","journal-title":"Lancet"},{"issue":"6","key":"1426_CR23","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jaad.2018.05.015","volume":"79","author":"AB Kimball","year":"2018","unstructured":"Kimball AB,\u00a0Sundaram M, Shields AL, et al. Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials. J Am Acad Dermatol. 2018;79(6):1141\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1426_CR24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al. Two phase\u00a03 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422\u201334.","journal-title":"N Engl J Med"},{"issue":"10443","key":"1426_CR25","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase\u00a03 trials. Lancet. 2024;403(10443):2504\u201319.","journal-title":"Lancet"},{"issue":"6","key":"1426_CR26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/bjd.21798","volume":"187","author":"B Midgette","year":"2022","unstructured":"Midgette B, Strunk A, Akilov O, et al. Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project. Br J Dermatol. 2022;187(6):927\u201335.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1426_CR27","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.jaad.2023.07.1035","volume":"89","author":"X Wei","year":"2023","unstructured":"Wei X, Passera A, Muscianisi E, et al. Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: results from the SUNSHINE and SUNRISE trials. J Am Acad Dermatol. 2023;89(6):1285\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1426_CR28","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401\u20139.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1426_CR29","first-page":"69","volume":"24","author":"MM Mukaka","year":"2012","unstructured":"Mukaka MM. Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24(3):69\u201371.","journal-title":"Malawi Med J"},{"issue":"1","key":"1426_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s13555-023-01085-w","volume":"14","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Kirby J, Ingram JR, et al. Burden of hidradenitis suppurativa: a systematic literature review of patient reported outcomes. Dermatol Ther (Heidelb). 2024;14(1):83\u201398.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1426_CR31","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.16672","volume":"179","author":"L Thorlacius","year":"2018","unstructured":"Thorlacius L, Ingram JR, Villumsen B, et al. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. Br J Dermatol. 2018;179(3):642\u201350.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1426_CR32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bjd.18648","volume":"182","author":"R Alhusayen","year":"2020","unstructured":"Alhusayen R. The pain of hidradenitis suppurativa: \u2018we only see what we know.\u2019 Br J Dermatol. 2020;182(1):17\u20138.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1426_CR33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/bjd.14475","volume":"175","author":"JR Ingram","year":"2016","unstructured":"Ingram JR, Hadjieconomou S, Piguet V. Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process. Br J Dermatol. 2016;175(2):263\u201372.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1426_CR34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jaad.2018.02.053","volume":"79","author":"A Garg","year":"2018","unstructured":"Garg A,\u00a0Papagermanos V, Midura M, Strunk A, Merson J. Opioid, alcohol, and cannabis misuse among patients with hidradenitis suppurativa: a population-based analysis in the United States. J Am Acad Dermatol. 2018;79(3):495-500.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1426_CR35","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1001\/jamadermatol.2019.2610","volume":"155","author":"S Reddy","year":"2019","unstructured":"Reddy S, Orenstein LAV, Strunk A, Garg A. Incidence of long-term opioid use among opioid-naive patients with hidradenitis suppurativa in the United States. JAMA Dermatol. 2019;155(11):1284\u201390.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1426_CR36","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000486741","volume":"233","author":"DE Lee","year":"2017","unstructured":"Lee DE, Clark AK, Shi VY. Hidradenitis suppurativa: disease burden and etiology in skin of color. Dermatology. 2017;233(6):456\u201361.","journal-title":"Dermatology"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01426-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01426-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01426-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T09:59:58Z","timestamp":1748685598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01426-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1426"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01426-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"John R. Ingram is a consultant for AbbVie, Boehringer Ingelheim, ChemoCentryx, Citryll, Insmed, Kymera Therapeutics, Novartis, UCB Pharma, UNION therapeutics, and Viela Bio. He is immediate-past Editor-in-Chief of the BJD and receives an authorship honorarium for two UpToDate HS chapters. He is co-copyright holder of HiSQOL and Investigator and Patient Global Assessment instruments for HS. His department receives income from copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments. Jacek C. Szepietowski has served as an advisor for AbbVie, LEO Pharma, Novartis, Pierre Fabre, Menlo Therapeutics, and Trevi; he has received speaker honoraria from AbbVie, Janssen-Cilag, LEO Pharma, Novartis, Sanofi-Genzyme, Sun Pharma and Eli Lilly, and he has received clinical trial funding from AbbVie, Almirall, Amgen, Galapagos, Holm, Incyte Corporation, InfraRX, Janssen-Cilag, Menlo Therapeutics, Merck, Novartis, Pfizer, Regeneron, Trevi and UCB. Lukasz Matusiak has been an advisory board\/consultant for AbbVie, Leo Pharma, Novartis, Pierre Fabre; a speaker for AbbVie, Janssen, Leo-Pharma, Novartis, Pierre Fabre, Valeant; Involved in clinical trials with AbbVie, Almirall, Amgen, Bio-Thera, BMS, Celltrion, Galderma, Galapagos, Incyte, InfraRX, Janssen, Kiniksa, Medimmune, Menlo Therapeutics, Novartis, Pfizer, Regeneron, UCB, Teva and Trevi. JSK has been an advisory board\/consultant for AbbVie, Bayer, ChemoCentryx, Incyte, Janssen, Novartis, Moonlake and UCB, and has received speaker fees from AbbVie, Janssen and UCB. Georgios Kokolakis reports consulting fees from Bayer; payment or honoraria from AbbVie, Abbott, Actelion Pharmaceuticals, Amgen, Basilea Pharmaceutica, Biogen IDEC, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Hexal, Janssen-Cilag, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Parexel, Pfizer and UCB; support for attending meetings or travel from AbbVie, Abbott, Amgen, Basilea Pharmaceutica, Celgene, Janssen-Cilag, LEO Pharma, MSD, Novartis, Pfizer, Sanofi and UCB, and served on a Data Safety Monitoring Board or Advisory Board for AbbVie, Abbott, Amgen, Basilea, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen-Cilag, LEO Pharma, Eli Lilly, Novartis, Takeda and UCB. Magdalena B. Wozniak is an employee and stockholder at Novartis Ireland Limited, Dublin, Ireland. Christine-Elke Ortmann, Angela Llobet Martinez, Nicolas Thomas and Ivette Alarcon are employees of Novartis Pharma AG, Basel, Switzerland. Shoba Ravichandran was an employee of Novartis Pharmaceuticals, East Hanover, New Jersey, USA at the time of the study, and is now retired. Christelle C. Pieterse is an employee of Syneos Health fully contracted to Novartis. Maryam S. Alam has been the principal investigator for clinical trials funded by Novartis, Arcutis Biotherapeutics, Galderma Laboratories, Eli Lilly, AbbVie, Pfizer, Concert pharmaceutical, Dermira pharmaceutical, UCB, Incyte, Boehringer Ingelheim, Amgen, Evelo Sciences, Leo Pharma, Bristol-Myers- Squibb, Dice Therapeutics, Kiniska Pharmaceuticals, Zai Lab co., Sanofi and Bausch Health. MSA has been on the advisory board for the following companies Amgen, AbbVie, Sanofi, Novartis, Incyte, Boehringer Ingelheim, UCB, Arcutis, Bristol-Myers- Squibb and Bausch Health. Dimitrios Ioannides has collaborated in educational and scientific activities and has taken part in advisory services of AbbVie, Amgen, Eli Lilly, Genesis, Janssen, Novartis, Pfizer, Sanofi and UCB. Alexa B. Kimball reports grants from AbbVie, Admirx, Anapyts Bio, Aristea, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, Moonlake, Novartis, Pfizer, Prometheus, Sanofi, Sonoma Bio and UCB, and fellowship funding from AbbVie and Janssen paid to her institution; royalties from BIDMC; honoraria or consulting fees from AbbVie, Alumis, Avalos, Bayer, Boehringer Ingelheim, Eli Lilly, Evoimmune, Innovaderm, Janssen, Novartis, Moonlake, Pfizer, Priovant, Sanofi, Sonoma Bio, Target RWE, UCB and Union Therapeutics; serving on advisory boards for Target RWE; serving as an advisory council member to the National Institute of Health Director; and serves on the board of directors of Almirall.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol and all amendments for the SUNSHINE and SUNRISE trials were reviewed by the independent ethics committee or institutional review board for each participating centre. The study was done according to The International Conference on Harmonisation Guidelines for Good Clinical Practice that have their origin in the Declaration of Helsinki. Written informed consent was obtained from each patient during the screening visit and before any study-specific procedure was done.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}